Toward a Pharmacogenetic Understanding of Nucleotide and Nucleoside Analogue Toxicity
نویسندگان
چکیده
منابع مشابه
Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity.
Antiretroviral therapies for HIV-1 infection have become progressively more potent and better tolerated. An important milestone was the 2001 Food and Drug Administration approval of tenofovir di-soproxil fumarate (TDF), a once-daily nucleotide analogue reverse-transcriptase in-hibitor that is available commercially as a single agent (Viread; Gilead Sciences), co-formulated with emtricitabine (T...
متن کاملNucleotide analogue inhibitors of purine nucleoside phosphorylase.
The diphosphate of the antiherpetic agent acyclovir [9-[(2-hydroxyethoxy)methyl]guanine] has been shown to inhibit purine nucleoside phosphorylase with unique potency (Tuttle, J. V., and Krenitsky, T. A. (1984) J. Biol. Chem. 259, 4065-4069). A major factor contributing to the superior inhibition by this diphosphate over the corresponding mono- and triphosphates is revealed here. Homologues of ...
متن کاملSafety and Toxicity of Individual Antiretroviral Agents in Pregnancy NUCLEOSIDE AND NUCLEOTIDE ANALOGUE REVERSE TRANSCRIPTASE INHIBITORS
There are currently six approved nucleoside analogue reverse transcriptase inhibitors. Data are available from clinical trials in human pregnancy for zidovudine and lamivudine, while didanosine and stavudine are under study. Zalcitabine and abacavir have not been studied in pregnant women. Tenofovir disoproxil fumarate is the first acyclic nucleotide analogue reverse transcriptase inhibitor. Th...
متن کاملInterferon-free strategies without a nucleoside/nucleotide analogue.
The identification of viral and host factors involved in hepatitis C virus (HCV) replication was a key prerequisite for the discovery and further exploration of antiviral drug targets. As of today, numerous direct-acting antiviral agents (DAAs), as well as host-targeting agents (HTAs), have been developed and entered clinical testing. The goal to omit pegylated interferon due to its unfavorable...
متن کاملInterferon-free strategies with a nucleoside/nucleotide analogue.
A key to effective interferon- (IFN-) free therapy for hepatitis C virus (HCV) infection is a direct-acting antiviral (DAA) with a high barrier to resistance that can act as the backbone to any regimen. Ideally, this agent should also be active against all HCV genotypes, be well tolerated and have few drug interactions. Nucleoside/nucleotide analogues (NAs) that inhibit the function of the HCV ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Infectious Diseases
سال: 2006
ISSN: 0022-1899,1537-6613
DOI: 10.1086/508550